MediWound Ltd. (MDWD)
| Market Cap | 216.82M +17.7% |
| Revenue (ttm) | 16.96M -16.1% |
| Net Income | -23.88M |
| EPS | -2.10 |
| Shares Out | 12.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 89,310 |
| Open | 16.56 |
| Previous Close | 16.52 |
| Day's Range | 16.18 - 17.21 |
| 52-Week Range | 14.14 - 22.51 |
| Beta | 0.15 |
| Analysts | Strong Buy |
| Price Target | 36.00 (+113.4%) |
| Earnings Date | May 20, 2026 |
About MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other ... [Read more]
Financial Performance
In 2025, MediWound's revenue was $16.96 million, a decrease of -16.14% compared to the previous year's $20.22 million. Losses were -$23.88 million, -20.99% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for MDWD stock is "Strong Buy" and the 12-month stock price target is $36.0.
News
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL ® Findings support o...
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic...
MediWound Files Annual Report on Form 20-F
MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announce...
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
EscharEx ® Phase III VALUE trial advancing as planned Expanded NexoBrid ® manufacturing facility operational ; regulatory approvals expected in 2026 $17 million revenue in 2025 ; $54 million in cash a...
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5 th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- Med...
MediWound to Present at Upcoming Investor Conferences
MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17 , 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t...
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
MediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
MediWound Reports New Clinical Data Demonstrating NexoBrid ® 's Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid ® Facility; Full Operational Capacity Expected by Year-End 2025 B...
MediWound to Report Third Quarter 2025 Financial Results
MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd.
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid ®
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
MediWound Expands Global Reach with Marketing Approval of NexoBrid ® in Australia
MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
MediWound's NexoBrid ® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global lead...
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, ...
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid ® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strate...
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
MediWound Announces New EscharEx ® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
MediWound to Report Second Quarter 2025 Financial Results
MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd.
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
VALUE Phase III trial of EscharEx ® in venous leg ulcers advancing as planned NexoBrid ® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of ...
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®'s superior clinical performance and comparable safety profile to SANTYL® Post hoc analysis published in the peer-re...
MediWound to Report First Quarter 2025 Financial Results
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
Presentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL ® , and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study ...
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for ...
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its f...
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
Findings in Burns Journal confirm NexoBrid's superiority over standard of care in pediatric patients with deep thermal burns NexoBrid is approved for pediatric use in the U.S., E.U. and Japan YAVNE, I...